A Phase 4, open-label, single-arm clinical study to describe safety and efficacy outcomes associated with the use of nirsevimab in neonates and infants born during or entering their first Respiratory Syncytial Virus (RSV) season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2026
This article has no abstract
Epistemonikos ID: 5fb3f745e01325c88165317f3da23980d81fa374
First added on: Oct 05, 2026